This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021.
The 340B program will be a major issue in 2021. I expect manufacturers to escalate their challenges to the contract pharmacy elements of the program. Meanwhile, covered entities will be battling manufacturers, state Medicaid programs, their contract pharmacy partners, and perhaps even HRSA itself. I'll share my thoughts on the latest developments during this Friday's webinar.
In the meantime, please enjoy my op-ed from September, which focuses on how 340B warps *prescription* prices (not drug list prices) and patient out-of-pocket costs. ICYMI, here are some clarifying comments on federally-qualified health centers (FQHCs).
Click here to see the original post and comments from September 2020.
Last Friday, The Wall Street Journal published my opinion piece: The Federal Program That Keeps Insulin Prices High. The article text is pasted below for those who don't subscribe.
I summarize issues with the role of contract pharmacies in the 340B Drug Pricing Program. My arguments will be familiar to regular readers of Drug Channels. I wrote this piece for a general business audience, so it's highly readable and omits industry insider terminology. To help you get the most from the article, I have included additional links to source materials in the text.
Please share your comments below and I'll respond where appropriate.
Source: Post feed
